

Haematologica  
HAEMATOL/2018/193854  
Version 4

Feasibility and efficacy of addition of individualized dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia

Arnon P. Kater, Marinus H.J. van Oers, Yvette van Norden, Lina van der Straten, Julia Driessen, Ward F.M. Posthuma, Martinus Schipperus, Martine E.D. Chamuleau, Marcel Nijland, Jeanette K. Doorduijn, Michel Van Gelder, Mels Hoogendoorn, Francien De Croon, Shulamiet Wittebol, J. Martijn Kerst, Erik W.A. Marijt, Reinier A.P. Raymakers, Martijn R. Schaafsma, Johan A. Dobber, Sabina A. Kersting, and Mark-David Levin  
(Collaborative Groups: HOVON CLL study group)

Disclosures: None

Contributions: APK, MHJvO, MEDC, EFMP, MS, M-DL designed the study; all authors collected the data; YvN analyzed the data; LvdS and JD wrote the manuscript with contributions from all authors, who also interpreted the data, read, commented on, and approved the final version of the manuscript; APK and M-DL supervised the study.